The U.S. cardiac resynchronization therapy market was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Surge in ...
The A-HIRATE Trial was a multicenter, prospective study assessing the incidence of atrial high rate episodes (AHRE) in pacemaker patients with and without previously diagnosed AT. The trial was ...
A pacemaker may be useful for atrial fibrillation (AFib ... electrical impulses to the heart to encourage a regular heart rhythm. People who get pacemakers may also need to take blood-thinning ...
Clinicians will increasingly encounter heart rhythm data generated from consumer-grade devices. Consumer-grade smartphone-paired devices and smartwatches have very high sensitivity and specificity for ...